KKKenji Kadomatsu

Kenji Kadomatsu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kenji Kadomatsu has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Daisuke Kamimura

    Department of Immunology and Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA

    1 shared publication
  • Haoqian Zhang

    Department of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan

    1 shared publication
  • Hiroshi Kojima

    Nagoya University Graduate School of Medicine, Nagoya, Japan

    1 shared publication
  • Kayaho Maeda

    Nagoya University Graduate School of Medicine, Nagoya, Japan

    1 shared publication
  • Kazuma Sakamoto

    Department of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya, Japan

    1 shared publication
  • Kenji Uchimura

    Department of Anatomy, Program in Immunology, University of California, San Francisco, California, USA

    1 shared publication

Latest Publications

  • Open Access

    CD147/Basigin Limits Lupus Nephritis and Th17 Cell Differentiation in Mice by Inhibiting the Interleukin‐6/STAT‐3 Pathway

    by Kayaho Maeda, Tomoki Kosugi, Waichi Sato, Hiroshi Kojima, Yuka Sato, Daisuke Kamimura, Noritoshi Kato, Naotake Tsuboi, Yukio Yuzawa, Seiichi Matsuo, et al.

    Objective: Interleukin‐17 (IL‐17)–producing T cells (Th17 cells) play critical roles in the pathogenesis of immune‐related diseases, including systemic lupus erythematosus. However, the fundamental mechanism regulating Th17 cell differentiation is not fully understood. Recently, we demonstrated that plasma levels of CD147/basigin (Bsg) in patients with lupus nephritis (LN) were closely associated with disease activity. but the molecular mechanism involving Bsg has been elusive. Here, we addressed the role of Bsg in the pathogenesis of LN.Methods: Injections of pristane (2,6,10,14‐tetramethylpentadecane [TMPD]) were administered to Bsg−/− or Bsg+/+ mice to induce LN. The mice were killed 6 months after being injected, for histologic and biochemical analyses of the kidneys and spleens.Results: Pristane induced LN more strikingly in Bsg−/− mice than in Bsg+/+ mice, even though humoral autoimmunity was similarly increased in both genotypes. The increased number of Th17, but not Th1, Treg cells, was augmented in Bsg−/− mice. The expression of IL‐17 was also increased in the kidneys of Bsg−/− mice, in proportion to LN disease activity. Furthermore, treatment with anti–IL‐17 antibody reduced LN disease activity in Bsg−/− mice. Complementary to these phenotypes of Bsg−/− mice, Bsg expression was enhanced in activated CD4+ T cells in vivo and in vitro. Bsg deficiency selectively augmented in vitro differentiation of naive CD4+ T cells to Th17 cells and STAT‐3 phosphorylation during this differentiation. Moreover, STAT‐3 phosphorylation was suppressed by crosslinking of Bsg with its antibody.Conclusion: Bsg plays an indispensable role in Th17 cell differentiation as a negative regulator by suppressing the IL‐6/STAT‐3 pathway.


  • Midkine in the pathology of cancer, neural disease, and inflammation

    by Kazuma Sakamoto, Kenji Kadomatsu

    Midkine (MK) is a heparin‐binding growth factor involved in various cellular processes such as cellular proliferation, survival, and migration. In addition to these typical growth factor activities, MK exhibits several other activities related to fibrinolysis, blood pressure, host defense and other processes. Many cell‐surface receptors have been identified to account for the multiple biological activities of MK. The expression of MK is frequently upregulated in many types of human carcinoma. Moreover, blood MK levels are closely correlated with patient outcome. Knockdown and blockade of MK suppress tumorigenesis and tumor development. Thus, MK serves as a tumor marker and a molecular target for cancer therapy. Furthermore, there is growing evidence that MK plays pivotal roles in neural and inflammatory diseases. Understanding of the mechanisms of action of MK is expected to create new therapeutic options for several human diseases.


  • Brain Keratan Sulfate and Glial Scar Formation

    by Haoqian Zhang, Kenji Uchimura, Kenji Kadomatsu

    Abstract:  In response to injury to the central nervous system (CNS), reactive astrocytes appear and accumulate in the wounded area, leading to glial scar formation. Glial scar is the physical barrier to axonal regeneration of injured neurons. Chondroitin sulfate proteoglycans are inhibitory to axon outgrowth and are upregulated in reactive astrocytes upon CNS injury. It is known that keratan sulfate proteoglycans (KSPGs) are also augmented after CNS injury and act as inhibitory cues. We give a brief overview of CNS injury and cover our recent data regarding the relationship between glial scar formation and KS. KS expression in the developing brain is detectable with 5D4, a KS‐specific monoclonal antibody. These 5D4 immunoreactivities are eliminated in mice deficient in N‐acetylglucosamine 6‐O‐sulfotransferase‐1. In adult mice, brain injury apparently upregulates mRNA expression of N‐acetylglucosamine 6‐O‐sulfotransferase‐1 as well as 5D4‐reactive KS in the wounded area. Intriguingly, the expression of 5D4‐reactive KS and reactive astrocyte accumulation in the wounded area are dramatically diminished in the sulfotransferase‐deficient mice. Consequently, the deficient mice exhibit a marked reduction in scar formation and enhancement of neuronal regeneration after brain injury. Thus, N‐acetylglucosamine 6‐O‐sulfotransferase‐1 plays indispensable roles in brain KS biosynthesis and glial scar formation after brain injury.


  • Open Access

    Homo‐oligomer formation by basigin, an immunoglobulin superfamily member, via its N‐terminal immunoglobulin domain

    by Seiya Yoshida, Maki Shibata, Satoshi Yamamoto, Masako Hagihara, Naoya Asai, Masahide Takahashi, Shigehiko Mizutani, Takashi Muramatsu, Kenji Kadomatsu

    Basigin (Bsg) is a highly glycosylated transmembrane protein with two immunoglobulin (Ig)‐like domains. A number of studies, including gene targeting, have demonstrated that Bsg plays pivotal roles in spermatogenesis, implantation, neural network formation and tumor progression. In the present study, to understand the mechanism of action of Bsg, we determined its expression status on the plasma membrane. Cotransfection of Bsg expression vectors with two different tags clarified that Bsg forms homo‐oligomers in a cis‐dependent manner on the plasma membrane. If the disulfide bond of the more N‐terminally located Ig‐like domain was destroyed by mutations, Bsg could not form oligomers. In contrast, the mutations of the C‐terminal Ig‐like domain or N‐glycosylation sites did not affect the association. The association of mouse and human Bsgs, which exhibit high homology in the transmembrane and intracellular domains but low homology in the extracellular domain, was very weak as compared with that within the same species, suggesting the importance of the extracellular domain in the association. If the extracellular domain of the human Ret protein was replaced with the N‐terminal Ig‐like domain of Bsg, the resulting chimera protein was associated with intact wild‐type Bsg, but not if the C‐terminal Ig‐like domain, instead of the N‐terminal one, of Bsg was used. No oligomer formation took place between the intact wild‐type Ret and Bsg proteins. In conclusion, these data indicate that the N‐terminal Ig‐like domain is necessary and sufficient for oligomer formation by Bsg on the plasma membrane.